Corcept Therapeutics Incorporated today announced that Study 06, the last of three Phase 3 trials evaluating CORLUX for treating the psychotic features of Psychotic Major Depression, did not achieve statistical significance with respect to its primary endpoint.
From: biz.yahoo.com
R) for Psychotic Major Depression Misses Primary Endpoint
Posted by Ruslan Abuzant at 9:07 PM
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment